康莱特注射液联合GP治疗晚期非小细胞肺癌的临床分析

Clincal analysis of Kanglaite Injection combined with GP chemotherapy in patients with advanced non-small cell lung cancer

目的探讨康莱特注射液联合吉西他滨^+顺铂(GP)化疗对晚期非小细胞肺癌(NSCLC)患者免疫功能、炎性因子的影响。方法随机将200例晚期NSCLC患者分为观察组(n=99)与对照组(n=101),观察组行康莱特注射液联合GP化疗,对照组采取单纯GP化疗,1周期21 d,干预2周期后评价各组疗效及不良反应;治疗前后测定两组患者血清免疫功能及炎性因子相关指标。结果观察组疾病控制率、存活质量改善率分别为82.83%、79.80%,均显著高于对照组的69.31%、63.37%(P<0.05)。与治疗前比较,治疗后对照组CD3^+、CD4^+、CD4^+/CD8^+均显著下降(P<0.05),而观察组无明显变化(P>0.05);观察组治疗后CD3^+、CD4^+、CD4^+/CD8^+分别为60.13±10.32、40.05±9.16、1.43±0.75,均显著高于对照组的52.07±10.13、31.30±8.74、0.96±0.58,差异有统计学意义(P<0.05)。与治疗前比较,两组治疗后血清CRP、TNF-α、IL-6水平均显著下降(P<0.05);观察组治疗后血清CRP、TNF-α、IL-6水平分别为(113.18±13.06)mg/L、(0.51±0.18)pg/ml、(13.42±2.17)pg/ml,均显著低于对照组的(156.17±20.36)mg/L、(1.10±0.20)pg/ml、(24.59±4.38)pg/ml,差异有统计学意义(P<0.05)。观察组白细胞减少、恶心呕吐、血小板减少发生率均显著低于对照组(P<0.05)。结论康莱特注射液联合GP化疗能有效提高晚期NSCLC患者疾病控制率,减少不良反应发生,且对免疫功能有保护作用,能显著降低炎性因子水平,改善患者存活质量。

Objective To analyze the effect of Kanglaite Injection combined with gemcitabine-cisplatin （GP） chemotherapy on the immune function and inflammatory factors in patients with advanced non-small cell lung cancer （NSCLC）. Methods According to different treatment methods, 200 patients with advanced NSCLC were divided into the observation group （ n =99） and the control group （ n =101）. The observation group was treated with Kanglaite Injection combined with GP chemotherapy, while the control group was treated with simple GP chemotherapy alone. 21 d was 1 cycle, and the curative effect and adverse reactions were evaluated after 2 weeks of intervention. The serum immune function related indicators and inflammatory factors in the two groups were determined before and after treatment. Results The disease control rate and the improvement rate of survival quality in the observation group were higher than those in the control group （ 82.83 % and 79.80% vs. 69.31% and 63.37%） （ P 〈0.05）. After treatment, CD3 ＋, CD4 ＋ and CD4 ＋/CD8 ＋ in the control group decreased significantly （ P 〈 0.05）, while there was no obvious change in the observation group （ P 〉0.05）. After treatment, CD3 ＋, CD4 ＋ and CD4 ＋/CD8 ＋ in the observation group [（60.13±10.32）, （40.05±9.16） and （1.43±0.75）] were significantly higher than those in the control group [（52.07±10.13） and （31.30±8.74） and （0.96±0.58）] （ P 〈0.05）. After treatment, levels of C reactive protein （CRP）, tumor necrosis factor α （TNF-α） and interleukin-6 （IL-6） in the two groups decreased significantly （ P 〈0.05）. The level in observation group [（113.18±13.06） mg/L, （0.51±0.18） pg/ml, （13.42±2.17） pg/ml] were significantly lower than those in the control group [（156.17±20.36） mg/L, （1.10±0.20） pg/ml, （24.59± 4.38 ） pg/ml] （ P 〈0.05）. The incidence rates of leukopenia, nausea and vomiting and thrombocytopenia in the observation group were significantly lower than those in the control group （ P 〈0.05）. Conclusion Kanglaite Injection combined with GP chemotherapy can effectively improve the disease control rate of patients with advanced NSCLC, reduce the incidence of adverse reactions, protect the immune function, significantly reduce the levels of inflammatory factors and improve the quality of life of patients.